Multiplex immunoassay for detection of immunoglobulin G to herpes simplex virus types 1, 2 and cytomegalovirus based on PHOSPHAN technology-Reference-Cited by-同舟云学术

Multiplex immunoassay for detection of immunoglobulin G to herpes simplex virus types 1, 2 and cytomegalovirus based on PHOSPHAN technology

Published:2017-04-20 Issue:2 Volume:62 Page:87-90
ISSN:2411-2097
Container-title:Problems of Virology, Russian journal
language:
Short-container-title:Voprosy virusologii

Author:

Nikitina A. V.¹,Pomelova V. G.¹,Osin N. S.²,Mardanly S. G.³

Affiliation:

1. State Research Institute of Biological Engineering

2. Immunoscreen, Closed Joint Stock Company

3. Ekolab, Closed Joint Stock Company

Abstract

We have developed a multiplex immunoassay test (immunochip) based on PHOSPHAN technology for the detection of immunoglobulin G to herpes simplex virus (HSV) types 1, 2 and cytomegalovirus (CMV). The immunochip consists of HSV type specific gG1 (HSV-1) and gG2 (HSV-2) recombinant antigens, the lysate antigen for detection of total IgG to both HSV types (HSV 1/2), and CMV specific chimeric recombinant antigen containing the immunodominant sequences of pp150, gB, pp28 and pp52 proteins. The sensitivity and specificity of simultaneous IgGs detection with recombinant proteins were comparable to the commercial ELISA kits regardless of the kind of investigated serum specimens (patient sera, standard serum panels). The lysate HSV antigen was as sensitive but significantly less specific, so that it could not be recommended for use as a component of the multiplex test. These results can be used as a basis for creating commercial multiplex tests intended for high-productive screening of HSV, CMV and other TORCH-infections in a clinical laboratory.

Publisher

Central Research Institute for Epidemiology

Subject

Infectious Diseases,Virology,General Medicine

Reference20 articles.

1. Brown Z.A. HSV-2 specific serology should be offered routinely to antenatal patients. Rev. Med. Virol. 2000; 10 (3): 141-4.

2. Newton E.R. Diagnosis of perinatal TORCH infections. Clin. Obstet. Gynecol. 1999; 42 (1): 59-70.

3. Benedetti J.K., Corey L., Asley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med. 1994; 121 (11): 847-54.

4. Koutsky L.A., Ashley R.I., Holmes K.K., Stevens C.E., Wolner-Hanssen P., Critchlow C.W. et al. The frequency of unrecognized type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex. Transm. Dis. 1990; 17 (2): 90-4.

5. Sucato G., Wald A., Wakabayashi E., Vieira J., Corey L. Evidence of latency and reactivation of both herpes simplex virus (HSV-1) and HSV-2 in the genital region. J. Infect. Dis. 1998; 177 (4): 1069-72.